Tsuchiya Takehiko, Nakahama Ken-Ichi, Asakawa Yasuyuki, Maemura Toshimitu, Tanaka Masanobu, Takeda Satoru, Morita Mineto, Morita Ikuo
Department of Cellular Physiological Chemistry, Graduate School, Tokyo Medical and Dental University, Tokyo, Japan.
Gynecol Endocrinol. 2009 Feb;25(2):104-9. doi: 10.1080/09513590802549841.
BACKGROUND: Angiogenesis is a critical factor in the progression of solid tumors and metastasis. The aim of this study was to characterise the roles of angiogenic and anti-angiogenic factors on ovarian cancer. METHODS: The expression levels of vascular endothelial growth factor (VEGF, angiogenic factor) and pigment epithelial growth factor (PEDF, anti-angiogenic factor) were measured by real-time polymerase chain reaction and Western blotting in ovarian tumors. Microvessel density (MVD) was evaluated by the total microvessel length in high-power field of tumor tissue preparations. RESULTS: MVD correlated with tumor malignancy. The tissues with the highest expression levels of VEGF (VEGF-H) were malignant tumors. The VEGF expression levels in some malignant tumors (VEGF-L) were as low as that in benign tumors. Therefore, the expression of PEDF was examined. The PEDF expression levels in VEGF-L malignant tumors were significantly lower than those in benign tumors. On the other hand, the PEDF expression levels in VEGF-H malignant tumor tissues were not significantly different from those in benign tumors. CONCLUSION: The reduction in PEDF expression levels may be, in part, responsible for tumor malignancy in VEGF-L ovarian tumors. Furthermore, PEDF may be a useful marker of malignancy in VEGF-L ovarian tumors.
背景:血管生成是实体瘤进展和转移的关键因素。本研究的目的是明确血管生成因子和抗血管生成因子在卵巢癌中的作用。 方法:通过实时聚合酶链反应和蛋白质印迹法检测卵巢肿瘤中血管内皮生长因子(VEGF,血管生成因子)和色素上皮衍生因子(PEDF,抗血管生成因子)的表达水平。通过肿瘤组织切片高倍视野下的微血管总长度评估微血管密度(MVD)。 结果:MVD与肿瘤恶性程度相关。VEGF表达水平最高的组织(VEGF-H)为恶性肿瘤。一些恶性肿瘤(VEGF-L)中的VEGF表达水平与良性肿瘤中的一样低。因此,检测了PEDF的表达。VEGF-L恶性肿瘤中的PEDF表达水平显著低于良性肿瘤中的。另一方面,VEGF-H恶性肿瘤组织中的PEDF表达水平与良性肿瘤中的无显著差异。 结论:PEDF表达水平降低可能部分导致了VEGF-L卵巢肿瘤的恶性程度。此外,PEDF可能是VEGF-L卵巢肿瘤恶性程度的有用标志物。
Cancer Gene Ther. 2004-5
Arch Otolaryngol Head Neck Surg. 2005-11
Oncotarget. 2019-10-15
Indian J Otolaryngol Head Neck Surg. 2014-1
Nat Rev Cancer. 2013-3-14